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Abstract
Introduction The identification of metabolomic dysregulation appears promising for the prediction of type 1 diabetes and 
may also reveal metabolic pathways leading to beta-cell destruction. Recent studies indicate that regulation of multiple 
phospholipids precede the presence of autoantigens in the development of type 1 diabetes.
Objectives We hypothesize that lipid biomarkers in plasma from children with recent onset type 1 diabetes will reflect their 
remaining beta-cell function and predict future changes in beta-cell function.
Methods We performed targeted lipidomic profiling by electrospray ionization tandem mass spectrometry to acquire compar-
ative measures of 354 lipid species covering 25 lipid classes and subclasses in plasma samples from 123 patients < 17 years 
of age followed prospectively at 1, 3, 6 and 12 months after diagnosis. Lipidomic profiles were analysed using liner regres-
sion to investigate the relationship between plasma lipids and meal stimulated C-peptide levels at each time point. P-values 
were corrected for multiple comparisons by the method of Benjamini and Hochberg.
Results Linear regression analysis showed that the relative levels of cholesteryl ester, diacylglycerol and triacylglycerol at 
1 month were associated to the change in c-peptide levels from 1 to 6 months (corrected p-values of 4.06E−03, 1.72E−02 
and 1.72E02, respectively). Medium chain saturated and monounsaturated fatty acids were the major constituents of the 
di- and triacylglycerol species suggesting a link with increased lipogenesis.
Conclusion These observations support the hypothesis of lipid disturbances as explanatory factors for residual beta-cell 
function in children with new onset type 1 diabetes.
Keywords Prediction and prevention of type 1 diabetes · Metabonomics · Diabetes in childhood
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PE(O)  Alkylphosphatidylethanolamine
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LPE  Lysophosphatidylethanolamine
PI  Phosphatidylinositol
LPI  Lysophosphatidylinositol
PS  Phosphatidylserine
PG  Phosphatidylglycerol
COH  Free cholesterol
CE  Cholesteryl ester
DG  Diacylglycerol
TG  Triacylglycerol
1 Introduction
The incidence of type 1 diabetes in childhood is increasing 
worldwide (Patterson et al. 2009; Soltesz et al. 2007). Across 
Europe the incidence rate of type 1 diabetes in childhood 
is increasing with approximately 3–4% per year (Patterson 
et al. 2012; Svensson et al. 2009). The exact mechanisms 
triggering and regulating progression towards beta-cell fail-
ure in type 1 diabetes are poorly understood but it is gen-
erally acknowledged that both genetic and environmental 
components are involved (Rewers and Ludvigsson 2016). 
Within a short time after disease onset approximately half of 
the patients will experience a remission phase or honeymoon 
period characterized by endogenous insulin production and 
an improved glycemic control (von Herrath et al. 2007). 
This has, been labelled by some (Muhammad et al. 1999), 
a ‘window of opportunity’ for treatment towards prevent-
ing the further immune destruction of the beta-cells or even 
restoration of the beta-cells.
Lipidomics systematically reflects the detectable lipids 
of cells, tissues and biofluids to capture a lipid snapshot of 
a given physiological and environmental milieu. The lipid-
omic phenotype is sensitive to subtle modifications in e.g. 
lifestyle and nutrition (Zheng and Qi 2014), and accordingly 
changes in the lipidome will reflect both genetic and envi-
ronmental factors, influencing susceptibility to developing 
chronic disease such as type 1 diabetes. Advanced technolo-
gies allow high-throughput profiling of the lipidome from 
a low volume blood specimen, and focus has been towards 
establishing lipidomic profiles that can predict disease sta-
tus and progression (Meikle et al. 2011; Weir et al. 2013). 
Recent research of the lipidome in relation to type 1 diabetes 
indicates that modulation of multiple serum phospholipids 
precedes the presence of autoantigens in the development 
of type 1 diabetes (Pflueger et al. 2011; Oresic et al. 2008). 
Children progressing to type 1 diabetes before 4 years of age 
had lower levels of phospholipids in their cord blood (La 
Torre et al. 2013). These observations suggest the poten-
tial of lipidomic biomarker panels in monitoring beta-cell 
function. Thus, we hypothesize that new biomarkers in the 
form of lipidomic panels in plasma from children with recent 
onset type 1 diabetes can predict decline or regeneration of 
the endogenous residual beta-cell function and may serve 
as markers for decline in beta-cell function before type 1 
diabetes manifests clinically.
In this study we profiled the plasma lipidome of a cohort 
of children diagnosed with type 1 diabetes and followed in 
the Danish Remission Phase Study. The objective of the 
study was to identify lipidomic profiles associated with the 
progression of the disease as assessed by changes in meal 
stimulated C-peptide levels within the first year after type 
1 diabetes onset.
2  Materials and methods
2.1  Study subjects
The Danish Remission Phase Study is a prospective long-
term observational study conducted in four pediatric depart-
ments in Denmark. Samples from a total of 123 children and 
adolescents aged less than 17 years with newly diagnosed 
type 1 diabetes enrolled from April 2004 to August 2006 
and were followed for 12 months from onset of type 1 dia-
betes, defined as the first insulin injection, were analyzed. 
The detailed study design has previously been described by 
Andersen et al. (2012). The study was performed accord-
ing to the criteria of the Helsinki II Declaration and was 
approved by the Danish National Committee on Biomedical 
Research Ethics (Journal Number: H-KA-04010-m). Older 
patients and all parents or guardians gave written informed 
consent. Data were transmitted anonymously by the centers; 
patients were identified by center number and patient code. 
Plasma samples from 1, 3, 6 and 12 months were analysed.
2.2  Residual beta‑cell function (stimulated 
C‑peptide)
Stimulated serum C-peptide was used as a marker of 
endogenous C-peptide release 1, 3, 6 and 12 after diagnosis 
(± 1 week) (Table 1). Stimulated C-peptide measurements 
under standardized conditions can be used as a clinically 
validated measurement of beta-cell function, as C-peptide 
is co-secreted in a one-to-one molar ratio to insulin (Palmer 
et al. 2004). There were 123 patients who contributed with 
at least one measurement during the first year. Blood was 
drawn 90 min after the ingestion of a liquid meal [Boost 
drink, formerly known as Sustacal (237 mL or 8 FL OZ 
containing 41 g carbohydrate, 10 g protein and 4 g fat, 
240 kcal): 6 mL/kg (maximal 360 mL), Novartis Medical 
Health, Inc., Minneapolis, MN, USA, http://www.boost 
.com] according to Diabetes Control and Complication trial 
(DCCT) standards (The Diabetes Control and Complications 
Trial Research Group 1998). Serum samples were labeled 
and frozen at − 80 °C until shipment on dry ice. Samples 
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were thawed twice for the C-peptide assay and aliquoting. 
Serum C-peptide was analyzed centrally using a fluoroim-
munometric assay after adding a standard as described thor-
oughly by Mortensen et al. (2010).
2.3  Extraction of lipids
Lipid species were extracted from plasma samples as 
described previously (Alshehry et al. 2015). Briefly, plasma 
(10 µL) was aliquoted into a 1.5 mL eppendorf tube using 
a positive displacement pipette and 100 µL of 1-butanol/
methanol (1:1, v/v), 5 mM ammonium formate containing 
internal standards (Supplementary Table 1) was added, also 
using a positive displacement pipette. The mixture was vor-
texed for 10 s, sonicated for 60 min in a sonic water bath 
(18–24 °C) and then centrifuged (16,000×g, 10 min, 20 °C). 
The supernatant was transferred into a 0.2 mL glass insert 
with Teflon insert caps for lipidomic analysis (Alshehry 
et al. 2015; Begum et al. 2017).
2.4  Lipidomics
In this study lipidomic analysis was performed by liquid 
chromatography electrospray ionisation tandem mass spec-
trometry on an Agilent 1290 liquid chromatography system 
combined with an Agilent 6490 triple quadrupole mass 
spectrometer as described previously (Mundra et al. 2018). 
We used scheduled multiple-reaction monitoring [MRM] 
in positive ion mode, building upon early methods (Meikle 
et al. 2011; Weir et al. 2013; Wong et al. 2013). The mass 
spectrometer was operated in dynamic/scheduled multiple 
reaction monitoring (dMRM) mode. There were 353 unique 
lipid species measured together with 13 stable isotope or 
non-physiological lipid standards (Supplementary Table 1). 
Mass spectrometer voltages used for the acquisition of data 
were; fragmentor voltage, 380 V and cell accelerator volt-
age, 5 V. The collision energy voltage was set individually 
for each lipid class as reported previously (Mundra et al. 
2018). There were several sets of isobaric lipids which 
shared the same nominal parent ion mass and also give rise 
to the same product ions. Specifically, for isobaric species 
of phosphatidylcholine, alkylphosphatidylcholine and alk-
enylphosphatidylcholine the parent and product ions (m/z 
184) were the same. As a result a single MRM transition 
was used to measure the corresponding species within each 
subclass, using an increased MRM window time (21 com-
binations). A total of 335 MRMs were used. Dwell time per 
MRM ranged between 7 and 100 ms depending on where 
within the gradient the measurement were made and how 
many concurrent MRMs were being measured.
The total run time per sample was 11 min. The total study 
analysis period was 120 h. Identical plasma quality control 
samples, obtained by combining plasma from six healthy 
adults (24–54 years) prepared immediately after collection 
and stored at − 80° until required for analysis were distrib-
uted throughout the extraction series of the patient plasma 
for every 15 patient samples, to monitor assay performance. 
The analysis was performed in one single analytical run with 
no breaks. Peak integration of both standards and plasma 
samples were performed using the MassHunter software, 
Agilent Technologies, with manual inspection. Concentra-
tions of the individual lipid species were estimated using a 
single point quantitation based on the area under the chroma-
tographic peak compared to the area under the peak for the 
relative internal standard (known amount). The total of each 
lipid class was calculated from the sum of the individual 
lipid species within that class. Identification of individual 
lipid species was based on the MRM experiment and reten-
tion time (MSI level 2) and was matched to previous frag-
mentation analysis in positive and negative ionization mode 
as described in detail by Weir et al. (2013).
A total of 353 lipid species were identified and 
quantified from the lipid classes: dihydroceramide 
(dhCer), ceramide (Cer), monohexosylceramide (MHC), 
Table 1  Clinical characteristic 
at the time of blood sampling
Characteristics at the time of blood samplings. Data is presented as mean (SD) where indicated
BMI body mass index, HbA1c haemoglobin A1c
*p < 0.05 in comparison between groups evaluated using ANOVA or Kruskal–Wallis
1 month 3 months 6 months 12 months
N (%male) 123 (52) 118 (51) 111 (53) 116 (51)
C-peptide (pmol/L)* 703.36 (395.02) 691.19 (445.29) 589.22 (417.29) 396.43 (371.43)
Height (cm) 144.38 (24.53) 145.33 (24.94) 147.84 (23.37) 149.61 (24.38)
Age (years) 10.08 (3.90) 10.11 (3.92) 10.34 (3.81) 10.17 (3.94)
Weight (kg) 39.79 (16.68) 40.71 (16.86) 42.41 (17.16) 43.79 (17.64)
Blood glucose after meal 
stimulation (pmol/L)*
14.56 (3.96) 15.34 (4.50) 17.86 (5.14) 19.93 (5.04)
BMI (kg/m2) 18.17 (2.77) 18.25 (2.78) 18.44 (3.07) 18.60 (2.93)
Hba1c (%)* 9.26 (1.20) 6.96 (0.88) 7.20 (1.21) 7.72 (1.36)
 A. J. Overgaard et al.
1 3
158 Page 4 of 9
dihexosylceramide (DHC), trihexosylceramide (THC), 
GM3 ganglioside (GM3), sphingomyelin (SM), phosphati-
dylcholine (PC), oxidized phosphatidylcholine (OxPC), 
alkylphosphatidylcholine (PC(O)), alkenylphosphati-
dylcholine (plasmalogen, PC(P)), lysophosphatidylcho-
line (LPC), lysoalkylphosphatidylcholine (lysoplatelet 
activating factor, LPC(O)), phosphatidylethanolamine 
(PE), alkylphosphatidylethanolamine (PE(O)), phos-
phatidylethanolamine plasmalogen (PE(P)), lysophos-
phatidylethanolamine (LPE), phosphatidylinositol (PI), 
lysophosphatidylinositol (LPI), phosphatidylserine (PS), 
phosphatidylglycerol (PG), free cholesterol (COH), cho-
lesteryl ester (CE), free cholesterol (COH), diacylglycerol 
(DG) and triacylglycerol (TG). The abbreviations listed 
here refer to the lipid classes and subclasses, the number 
of carbons and double bonds will be listed when refer-
ring to individual lipid species, such as LPC(22:6) which 
defines a lysophosphatidylcholine containing a fatty acid 
comprising 22 carbon atoms and six double bonds. Meas-
urements of lipids composed of two fatty acids are deter-
mined as the sum of the carbons and the double bonds 
across both fatty acids, e.g. PC(36:4) based on previous 
methods (Weir et al. 2013; Meikle et al. 2013). The blood 
samples used in this study were collected in 2004 and have 
been stored at − 80 °C since, and only thawed once before 
the analysis, which should not have any impact on stability 
of most lipid species (Yao and Vance 1988; Hyötyläinen 
and Orešič 2015).
2.5  Normalization of lipidomics data
Total content of phosphatidylcholine within each sample, 
the most abundant phospholipid species in blood, was used 
as an internal reference and lipids were normalized to this 
(concentration of individual lipid species/concentration of 
phosphatidylcholine. The statistical analysis of phosphati-
dylcholine class was performed on raw data). Before sta-
tistical analysis, lipidomic data was log 10 (hereafter log) 
transformed and normalized to the inter-quartile range.
2.6  Statistical analysis
Differences between time points in clinical and anthropo-
metric data were evaluated using ANOVA or Kruskal–Wallis 
in SPSS. Linear regression models were completed using 
MatLab or R and all models included the covariates sex, age, 
HbA1c and 1 month C-peptide levels, except in the cases 
where models evaluated change in C-peptide over time, 
where C-peptide levels at 1 month were left out. Correction 
for multiple testing was done using the Benjamini–Hochberg 
method (Benjamini 1995).
3  Results
3.1  Demographic and clinical characteristics
123 patients were enrolled in the study whereof 52% were 
male. Clinical information including anthropometric data 
is summarized in Table 1.
Throughout the first 12 months several of the patients 
had short periods of remission, defined as > 300 pmol/L 
meal stimulated C-peptide. The weight, height and the 
BMI accordingly, increased significantly throughout the 
study period. HbA1c levels were significantly higher at 
1 month. Blood glucose levels after meal stimulation were 
significantly higher after 12 months duration of diabetes. 
C-peptide levels at 1  month were not associated with 
bicarbonate levels at diagnosis (as a measure of ketoaci-
dosis) when adjusted for age and sex (data not shown).
3.2  Lipidomic assay performance
The median percentage coefficient of variation (%CV) for 
the individual lipid species within the quality control sam-
ples of the analysis was 12.4% with 90% of lipids having 
CVs < 20%. Supplementary figure 1 depicts a Principal 
component analysis (PCA) plot of the QC samples.
3.3  Lipid classes associated with change 
in C‑peptide
Table 2 shows change in C-peptide levels from 1 month 
to 3, 6 and 12 months associated with an inter-quartile 
change from the 25 to 75 percentile of the respective lipid 
classes at the 1 month.
Cholesteryl ester, triacylglycerol and diacylglycerol 
levels at 1 month were significant predictors of a decrease 
in C-peptide over 6 months and after 12 months how-
ever at 12 months the associations did not maintain sig-
nificance after correction for multiple testing. Oxidized 
phosphatidylcholine levels at 1 month were predicting an 
increase in C-peptide after 6 and 12 months although this 
was not significant after Benjamini–Hochberg correction. 
Furthermore, ceramide and GM3 ganglioside predicted a 
decrease in C-peptide after 12 months; phosphatidylglyc-
erol predicted a decrease in C-peptide after 6 months and 
alkylphosphatidylethanolamine an increase in C-peptide 
after 12 months but again, did not maintain significance 
after correction. Monohexocylceramide and cholesteryl 
ester were predictors of a decrease in C-peptide after 
3 months before correction for multiple testing.
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3.4  Lipid species associated with change 
in C‑peptide
Nine diacylglycerol species, seven of which were carrying 
16:1 and/or 18:1 fatty acids, were associated with a decrease 
in C-peptide after 6 months (Table 3).
Eight triacylglycerols were also associated with a 
decrease in C-peptide after 6 months. All of the triacylglyc-
erols contained at least one 16:1 or 18:1 fatty acid. Seven 
cholesteryl esters were associated with a decrease in C-pep-
tide at 6 months. Supplementary Table 2 lists the association 
of all lipid species to the change in C-peptide over time.
3.5  Lipid species associated with C‑peptide levels
Linear regressions between lipid species and C-peptide, 
adjusted for age, sex and HbA1c were performed at each 
time point. At 1  month the LPC(20:2), LPC(22:5) and 
SM(32:0) species were significantly negatively associated 
to C-peptide levels after correction for multiple testing 
and at 1 month, cholesteryl esters were associated to lower 
C-peptide levels at 6 months (Table 4).
3.6  Change in lipid associated to change 
in C‑peptide
In order to assess the relationship between changes in plasma 
lipids and changes in C-peptide we performed linear regres-
sion between the changes in these measures, from 1 month to 
each other time point. There was no significant relationship 
between change in lipids and change in C-peptide levels.
4  Discussion
This study aimed to investigate the lipidome in relation 
to beta-cell function in children the first year after type 1 
diabetes debut. Several lipid classes were associated with 
a decrease in beta-cell function after diagnosis of type 1 
diabetes and the level of oxidized phosphatidylcholine could 
predict an increase in C-peptide over time, although signifi-
cance did not remain after correction for multiple testing.
Lipids involved in energy metabolism were generally 
predictors of lower C-peptide levels. At 1 month, the lipid 
classes triacylglycerol and diacylglycerol, and several spe-
cies of these, were associated with a decrease in stimulated 
C-peptide levels after 6 months (Table 2). Intensive insu-
lin therapy has been shown to increase triacylglycerol and 
weight gain in the DCCT study (Purnell et al. 2013). In the 
present study higher levels of triacylglycerols were associ-
ated with a significant decrease in C-peptide over 6 months. 
Low triacylglycerol levels have been identified in cord-
blood of children developing type 1 diabetes before 2 years 
of age, but were also related to shorter gestational age (La 
Torre et al. 2013). Short gestational age is in itself related 
to type 1 diabetes (Dahlquist and Kallén 1992), and it can 
be speculated that low levels of triacylglycerol might be an 
accelerator- or sign of metabolic deviations leading to type 
1 diabetes at very early ages. In the present study high tria-
cylglycerol levels at onset were associated with a decrease 
in stimulated C-peptide at 6 months (Table 2), indicating 
that triacylglycerol levels affect or reflect type 1 diabetes 
progression differently depending on when in the disease 
pathogenesis these are measured. At type 1 diabetes onset, 
triacylglycerols could possibly act as a metabolic accelera-
tor for beta-cell destruction similar to lipotoxicity known 
from the progression of type 2 diabetes (Yang and Li 2012). 
Of note, all of the triacylglycerol species contained a 16:1 
fatty acid and some also a 18:1 fatty acid, which are pri-
mary products of lipogenesis, further suggesting an altered 
metabolism leading to an increase in beta cell loss (Burns 
Table 3  Lipid species associated with change in C-peptide adjusted 
for age, sex and HbA1c
a Associated with an IQR increase in Predictor (1  month lipid) con-
centration
Lipid species Change in C-peptide, 1 to 6 month
Change in outcome 
(pmol/L)a (95% CI)
p-value p-value 
(Benjamini–
Hochberg)
CE(16:1) − 140.9 (− 220, − 62) 7.4E−04 2.7E−02
CE(16:2) − 134.2 (− 221, − 47) 3.2E−03 4.7E−02
CE(18:1) − 122.8 (− 199, − 47) 2.1E−03 4.3E−02
CE(18:2) − 153.6 (− 228, − 79) 1.1E−04 1.3E−02
CE(18:3) − 150.8 (− 236, − 66) 7.7E−04 2.7E−02
CE(22:5) − 123.6 (− 199, − 48) 1.8E−03 4.3E−02
CE(22:6) − 109.7 (− 181, − 38) 3.3E−03 4.7E−02
DG(14:0/16:0) − 147.5 (− 234, − 61) 1.1E−03 3.2E−02
DG(14:0/16:1) − 173.6 (− 253, − 95) 3.8E−05 7.4E−03
DG(14:0/18:1) − 162.4 (− 257, − 68) 1.1E−03 3.2E−02
DG(14:0/18:2) − 148.4 (− 240, − 57) 2.0E−03 4.3E−02
DG(16:0/16:1) − 159.6 (− 239, − 80) 1.6E−04 1.4E−02
DG(16:0/18:1) − 135.3 (− 216, − 55) 1.4E−03 3.7E−02
DG(16:1/16:1) − 191.7 (− 279, − 104) 4.2E−05 7.4E−03
DG(16:1/18:1) − 165.5 (− 250, − 81) 2.1E−04 1.5E−02
DG(18:1/18:1) − 130.2 (− 213, − 47) 2.7E−03 4.6E−02
TG(14:0/16:1/18:1) − 156.7 (− 258, − 55) 3.1E−03 4.7E−02
TG(14:0/16:1/18:2) − 151.5 (− 243, − 60) 1.6E−03 4.0E−02
TG(14:1/16:1/18:0) − 171.9 (− 269, − 75) 7.1E−04 2.7E−02
TG(16:0/16:1/18:1) − 154.3 (− 252, − 57) 2.5E−03 4.6E−02
TG(16:1/16:1/16:1) − 175.6 (− 274, − 77) 7.1E−04 2.7E−02
TG(16:1/16:1/18:1) − 167.7 (− 261, − 74) 6.5E−04 2.7E−02
TG(16:1/18:1/18:1) − 129.0 (− 213, − 45) 3.2E−03 4.7E−02
TG(16:1/18:1/18:2) − 120.9 (− 198, − 44) 2.7E−03 4.6E−02
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et al. 2012). At a cellular level, studies on min6 cells and 
isolated mouse pancreatic islets have shown an increase in 
the conversion of triacylglycerols to diacylglycerols during 
glucose stimulation (Pearson et al. 2016). DG(16:0/18:1) 
is likely the most abundant product of glucose stimulated 
triacylglycerol hydrolysis (Pearson et al. 2016), in our study 
this specie was associated with a decrease in C-peptide after 
6 months, indicating a potential link between glucose levels 
at 1 month and a significant higher decrease in c-peptide 
over time. The end product of hydrolysis of triacylglycerols 
are monoacylglycerols, unfortunately our analysis did not 
include these low abundance lipid species.
At 1 month, the total level of triacylglycerol was associ-
ated with both weight and age which were themselves highly 
correlated. To avoid adjusting for highly correlated covari-
ates we selected age as the most appropriate covariate in this 
adolescent cohort.
Seven cholesteryl ester species, at 1 month, were predic-
tors of a decrease in C-peptide after 6 months. A previous 
study suggests that an increase in inflammatory cytokines 
might facilitate the uptake of cholesteryl ester enriched lipo-
proteins into the tissues in otherwise normolipidemic type 
1 diabetes patients, and this connection also explains the 
increased risk of atherogenesis in type 1 diabetes patients 
(Ruan et al. 2006). In this context the higher level of choles-
teryl esters at 1 month that is associated with higher loss of 
beta-cell function, is in contradiction to previous findings 
where increases in inflammatory cytokines in circulation has 
been associated with a more severe beta-cell loss over time 
(Kaas et al. 2012). Nevertheless, we have not yet investigated 
cytokine levels in relation to stimulated C-peptide levels in 
this particular cohort and cannot conclude on their effect on 
cholesteryl esters.
Sphingolipid metabolites, such as sphingomyelin, GM3, 
ceramides and the precursor and metabolites of ceramide, 
dihydroceramide, monohexosylceramide, dihexosylceramide 
and trihexosylceramide, were overall associated with a lower 
C-peptide level after 3, 6 and 12 months (Table 2), although 
not reaching significance after correction for multiple test-
ing. The sphinghomyelin SM(32:0) level at 1 month was 
significantly associated with C-peptide levels (Table 4). 
Sphingolipids modulate several beta-cell signaling pathways 
involved in the progression of diabetes such as apoptosis, 
cytokine secretion, ER to golgi trafficking, islet autoim-
munity and insulin gene expression and furthermore, sphin-
golipid metabolism on internal membranes is also implicated 
in the regulation of beta-cell apoptosis. Recent advances in 
technology has facilitated investigating the role of ceramides 
in beta-cell dysfunction, and the current debate on the role of 
ceramides in type 1 diabetes focuses on whether ceramides 
can mimic the effects of IL-1β in promoting beta-cell death 
and in repressing insulin production (Boslem et al. 2012). 
The mentioned functions of sphingolipids are executed pri-
marily within the cells, whereas our data is from lipids in 
circulation. Whether circulating lipid levels reflect beta cell 
lipid metabolism remains to be elucidated.
Two different lysophosphatidylcholine species were 
associated with a lower C-peptide level at 1  month 
(Table 4). Lower levels of lysophosphatidylcholine in cord 
blood in a population of children progressing to type 1 
diabetes mellitus before the age of four have previously 
been identified (La Torre et al. 2013), but this study also 
revealed an association of low lysophosphatidylcholine 
levels to gestational infections, however, infections with 
coxsackie virus during pregnancy has previously shown 
no association to induction of islet autoimmunity in the 
offspring (Füchtenbusch et al. 2001).
Oxidized phosphatidylcholine levels at 1 month were 
predictors of an increase in C-peptide levels at 6 and 
12 months (Table 2) although this did not reach signifi-
cance after correction for multiple testing. The coefficient 
of variation of total oxidized phosphatidylcholine were 
43.3% in the quality control samples, and 20.4% in the 
technical quality control samples indicating low reproduc-
ibility of these particular MRMs, so caution should be 
made when interpreting these results. Oxidation of lipids 
occurs in both initiation and resolution of inflammation as 
pro-inflammatory and anti-inflammatory mediators. For 
instance, eicosanoids, signaling molecules participating 
in the initiation of the early events in acute inflamma-
tion, are derived from oxidation of 20 carbon fatty acids 
(Lei et al. 2015). In this study a higher level of oxidized 
Table 4  Lipid classes and 
species at 1 month significantly 
associated with C-peptide levels 
adjusted for age, sex and HbA1c
At time points other than 1 month, regressions were also corrected for c-peptide levels at 1 month
a Associated with an IQR increase in Predictor (1 month lipid) concentration
Lipid Outcome Outcome (pmol/L)a (95% CI) p-value p-value (Benja-
mini–Hochberg)
LPC(20:2) C-peptide at 1 month − 132.3 (− 196, − 69) 8.3E−05 1.5E−02
LPC(22:5) C-peptide at 1 month − 136.3 (− 201, − 71) 7.6E−05 1.5E−02
SM(32:0) C-peptide at 1 month − 149.2 (− 228, − 71) 3.0E−04 3.6E−02
Total CE C-peptide at 6 months − 133.1 (− 213, − 53) 1.5E−03 3.8E−02
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phosphatidylcholine at 1 month was predictive of an 
increase in C-peptide after 6 and 12 months, suggesting 
that oxidized phosphatidylcholine in this situation may be 
mediating anti-inflammatory pathways.
A limitation of this study, as with most lipidomics stud-
ies, is the inability to identify double bond position in the 
acyl chains of lipid species. The lipidomic analysis per-
formed in this study was based on scheduled MRM with 
internal lipid standards for each class of lipids added to 
the samples with the limitation of not reflecting the point 
of saturations in the various fatty acid chains in the lipids. 
While methods to determine acyl chain double bond posi-
tion do exist these are not compatible with high through 
put quantification. Another limitation of the study is the 
lack of lipidomic profiles from healthy controls. Ethically, 
it is very challenging to justify including healthy children 
in studies where blood samples are drawn, and we have not 
been successful in obtaining blood samples from healthy 
children yet.
5  Conclusions
This study provides further evidence for the potential of 
lipidomic profiles in assessing beta-cell function in type 1 
diabetes, and the effects of dysregulated lipid metabolism on 
the progression of beta-cell destruction. Future studies will 
aim at investigating prediction and progression models for 
the development of type 1 diabetes before seroconversion in 
genetically high-risk children.
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